Viral recombinant vaccines to the E6 and E7 antigens of HPV-16

Virology

Volumn 270, Issue 1, 2000, Pages 146-161

  He, Z ^a   Wlazlo, A P ^a   Kowalczyk, D W ^a   Cheng, J ^a   Xiang, Z Q ^a   Giles Davis, W ^a   Ertl, H C J ^a  

^a WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYTOKINE; GAMMA INTERFERON; RECOMBINANT INTERLEUKIN 1; RECOMBINANT INTERLEUKIN 2; RECOMBINANT VACCINE; SYNTHETIC PEPTIDE; VIRUS ANTIGEN; VIRUS DNA; VIRUS GLYCOPROTEIN; VIRUS VACCINE;

ADENOVIRUS; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; IMMUNIZATION; LUNG METASTASIS; MOUSE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL; UTERINE CERVIX CANCER; VACCINATION; VACCINIA VIRUS; VIRUS INFECTION;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; HUMAN PAPILLOMAVIRUS TYPE 16; PAPILLOMAVIRUS; VACCINIA; VACCINIA VIRUS;

EID: 0034712873     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2000.0271     Document Type: Article

References (51)

1. Aldovini A., Young R. A. Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines. Nature. 351:1991;479-481.
2. Benacerraf B., McDevitt H. O. Histocompatibility-linked immune response genes. Science. 175:1972;273-279.
3. Bonnez W., DaRin C., Borkhuis C., de Mesy Jensen K., Reichman R. C., Rose R. C. Isolation and propagation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse. J. Virol. 72:1998;5256-5261.
4. Borysiewicz L., Fiander A., Nimako M., Man S., Wilkinson G., Westmoreland D., Evans A., Adams M., Stacey S., Boursnell M., Rutherford E., Hickling J., Inglis S. C. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet. 347:1996;1523-1527.
5. Cameron P. U., Freudenthal P. S., Barker J. M., Gezelter S., Inaba K., Steinman R. M. Dendritic cells exposed to human immunodeficiency virus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science. 257:1992;383-387.
6. Charabarti S., Brechling K., Moss B. Vaccinia virus vector: Coexpression of β-galactosidase provides visual screening of recombinant viral plaques. Mol. Cell. Biol. 5:1985;3403-3409.
7. Chen L., Thomas E., Hu S., Hellstrom I., Hellstrom K. E. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc. Natl. Acad. Sci. USA. 88:1991;110-114.
8. Christensen N., Kreider J., Kan N., DiAngelo S. L. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody-inducing neutralizing epitopes. Virology. 181:1991;572-579.
9. Dalton D., Patti-Meek S., Keshaw S., Figam I., Bradley A., Steward J. A. Multiple defects of immune cell function in mice with disrupted interferon-γ genes. Science. 259:1993.
10. De Bruijn M. L. H., Schuurhuis D. H., Vierboom M. P. M., Vermeulen H., de Cock K. A. J., Ooms M. E., Ressing M. E., Toebes M., Franken K. L. M. C., Drijfhout J.-W., Ottenhoff T. H. M., Offringa R., Melief C. J. M. Immunization with human papillomavirus type-16 (HPV16) oncoprotein loaded dendritic cells as well as protein in adjuvant induces MHC class I restricted protection to HPV16-induced tumor cells. Cancer Res. 58:1998;724-731.
11. Dyson N., Howley P., Munger K., Harlow E. The human papillomavirus type 16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 243:1989;934-937.
12. Ertl H. C. J., Finberg R. W. Sendai virus-specific T-cell clones: Induction of cytolytic T cells by an anti-idiotypic antibody directed against a helper T-cell clone. Proc. Natl. Adad. Sci. USA. 81:1984;2850-2854.
13. Ertl H. C. J., Finberg R. W. Characteristics and functions of sendai virus-specific T-cell clones. J. Virol. 50:1984;425-431.
14. Fries L., Gordon D., Richards R., Egan J., Hollingdale M., Gross M., Silverman C., Alving C. R. Liposomal malaria vaccine in humans: A safe and potent adjuvant strategy. Proc. Natl. Acad. Sci. USA. 89:1992;258-362.
15. Ginsberg H., Lundholm-Beuchamp U., Horswood R., Pernis B., Wold W., Chanock R., Prince G. A. Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc. Natl. Acad. Sci. USA. 86:1989;3823-3827.
16. Graham F., Smiley J., Russell W., Nairn R. Characterization of a human cell line transformed by DNA from adenovirus 5. J. Gen. Virol. 36:1977;59-72.
17. Guller M. L., Jacobson N. G., Gubler U., Murphy K. M. T cell genetic background determines default T helper phenotype development in vitro. J. Exp. Med. 181:1995;713-721.
18. Halbert C., Galloway D. A. Identification of the E5 open reading frame of human papillomavirus type 16. J. Virol. 62:1988;1071-1075.
19. Harvey M., Levine A. J. P53 alteration is a common event in the spontaneous immortalization of primary P53 embryo fibroblasts. Genes Dev. 5:1991;2375-2385.
20. Ji H., Chang E. Y., Lin K.-Y., Kurman R. J., Pardoll D. M., Wu T.-C. Antigen-specific immunotherapy for murine lung metastatic tumors expressing human papillomavirus type 16 E7 oncoprotein. Int. J. Cancer. 78:1998;41-45.
21. Jochmus I., Osen W., Altmann A., Buck G., Hofmann B., Schneider A., Gissman L., Rammensee H.-G. Specificity of human cytotoxic T lymphocytes induced by a human papillomavirus type 16 E7 derived peptide. J. Gen. Virol. 78:1997;1689-1695.
22. Kadish A. S., Ho G. Y. F., Burk R. D., Wang Y., Romney S. L., Ledeidge R., Angeletti R. H. Lymphoproliferative responses to HPV type 16 proteins E6 and E7: Outcome of HPV infection and associated neoplasia. J. Natl. Cancer Inst. 89:1997;1485-1493.
23. Kreider J. W., Howett M. K., Wolfe S. A., Bartlett G. L., Zaino R. J., Sedlacek T., Mortel R. Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata. Nature. 317:1985;639-641.
24. Kuhn R., Rajewsky K., Muller W. Generation and analysis of interleukin-4 deficient mice. Science. 254:1991;707-709.
25. Lin K., Guarnieri F., Staveley-O'Carroll K., Levitsky H., August J., Pardoll D., Wu T. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:1996;21-26.
26. Meneguzzi G., Cerni C., Kieny M. P., Lathe R. Immunization against human papillomavirus type 16 tumor cells with recombinant vaccinia viruses expressing E6 and E7. Virology. 181:1991;62-69.
27. Meyers C., Mayer T. J., Ozbun M. A. Synthesis of infectious human papillomavirus type 18 in differentiating epithelium transfected with viral DNA. J. Virol. 71:1997;7381-7386.
28. Morein B. The ISCOM antigen-presenting system. Nature. 332:1988;287-288.
29. Murali-Krishna K., Altman J. D., Suresh M., Sourdive D. J. D., Zajac A. J., Miller J. D., Slansky J., Ahmed R. Counting antigen-specific CD8 cells: A reevaluation of bystander activation during viral infection. Immunity. 8:1998;177-187.
30. Overell R., Wisser K., Cosman D. Stably transmitted triple promoter retroviral vectors and their use in transformation of primary mammalian cells. Mol. Cell. Biol. 8:1988;1803-1808.
31. Penn I. The effect of immuno-suppression on pre-existing cancer. Transplantation. 55:1993;742-747.
32. Perkus M. E., Limbach K., Paoletti E. Cloning and expression of foreign genes in vaccinia virus using a host range selection system. J. Virol. 63:1989;3829-3836.
33. Poirer J., Kehoe M., Beachey E. Protective immunity provoked by oral administration of attenuated aroA Salmonella typhimurium expressing cloned streptococcal M protein. J. Exp. Med. 168:1988;25-32.
34. Schwartz E., Freese U. K., Gissman L. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 314:1985;111-114.
35. Seedorf K., Krammer G., Durst M., Suhai S., Rowekamp W. G. Human papillomavirus type 16 DNA sequence. Virology. 145:1985;181-185.
36. Sundaram P., Tigelaar R. E., Xiao W., Brandsma J. L. Intracutaneous vaccination of rabbits with the E6 gene of cottontail rabbit papillomavirus provides partial protection against virus challenge. Vaccine. 16:1998;613-623.
37. Sundberg J. P., O'Banion M. K. Animal papillomaviruses associated with malignant tumors. Adv. Viral. Oncol. 8:1989;55-71.
38. Tarpey I., Stacey S., McIndoe A., Davies D. H. Priming in vivo and quantification in vitro of class I MHC-restricted cytotoxic T cells to human papillomavirus type 11 early proteins (E6 and E7) using immunostimulating complexes (ISCOM's). Vaccine. 14:1996;230-236.
39. Van den Brule A. J. C., Snijders P. J. F., Meijer C. J. L. M., Waldboomers J. M. M. PCR based detection of genital HPV genotypes: An update and future perspecives. Papillomavirus Rep. 4:1993;95-99.
40. Vierboom M. P. M., Feltkamp M. C. W., Neisig A., Drijfhout J. W., Ter Schegget J., Neefjees J. J., Melief C. J. M., Kast W. M. Peptide vaccination with an anchor-replaced CTL epitope protects against human papillomavirus type 16-induced tumors expressing the wild-type epitope. J. Immunother. 21:1998;399-408.
41. Vierboom M. P. M., Nijman H. W., Offringa R., van der Voort E. I. H., van Hall T., van den Broek L., Fleuren G. J., Kenemans P., Kast W. M., Melief C. J. M. Tumor eradication by Wild-type p53 specific cytotoxic T lymphocytes. J. Exp. Med. 186:1997;695-704.
42. Wang B., Kennan W. S., Yasukawa-Barnes J., Lindstrom M. J., Gould M. N. Carcinoma induction following direct in situ transfer of v-Ha-ras into rat mammary epithelial cells using replication-defective retroviral vector. Cancer Res. 51:1991;2642-2648.
43. Werness B., Levine A., Howley P. M. Association of human papillomavirus type 16 and 18 E6 proteins with p53. Science. 248:1990;76-79.
44. Wiktor T., MacFarlan R., Reagan K., Dietzschold B., Curtis P., Wunner W., Kieny M., Lathe R., Lecoq J., Mackett M., Moss B., Koprowski H. Protection from rabies by a vaccinia rabies recombinant containing the rabies virus glycoprotein gene. Proc. Natl. Acad. Sci. USA. 81:1984;7194-7198.
45. Xiang Z., Yang Y., Wilson J., Ertl H. C. J. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology. 219:1996;220-227.
46. Xiang Z., Knowles B., McCarrick J., Ertl H. C. J. Immune effector mechanisms required for protection to rabies virus. Virology. 214:1995;389-404.
47. Yang Y., Li Q., Ertl H., Wilson J. W. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenovirus. J. Virol. 69:1995;2004-2015.
48. Yang Y., Jooss K., Su Q., Ertl H., Wilson J. M. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3:1996;137-144.
49. Yang Y., Okayama H., Howley P. M. Bovine papillomavirus contains multiple transforming genes. Proc. Natl. Acad. Sci. USA. 83:1985;2200-2203.
50. + cytolytic T cells. Nature. 344:1990;742-746.
51. Zur Hausen H. Viruses in human cancers. Science. 254:1991;1167-1173.